Overactive Bladder Treatment Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Publication Month: Nov 2020 | No. of Pages: 84 Published By: 99Strategy
Single User License: US $ 2800
Corporate User License: US $ 5600

Summary

Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.

The global Overactive Bladder Treatment market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Overactive Bladder Treatment market segmented into
Idiopathic Overactive Bladder
Mirabegron
Botox

Based on the end-use, the global Overactive Bladder Treatment market classified into
Idiopathic Overactive Bladder
Neurogenic Overactive Bladder

Based on geography, the global Overactive Bladder Treatment market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are
Astellas Pharma
Allergan
Pfizer
Teva (Activas)
Johnson & Johnson

Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL OVERACTIVE BLADDER TREATMENT INDUSTRY
2.1 Summary about Overactive Bladder Treatment Industry
2.2 Overactive Bladder Treatment Market Trends
2.2.1 Overactive Bladder Treatment Production & Consumption Trends
2.2.2 Overactive Bladder Treatment Demand Structure Trends
2.3 Overactive Bladder Treatment Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Anticholinergics
4.2.2 Mirabegron
4.2.3 Botox
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Idiopathic Overactive Bladder
4.3.2 Neurogenic Overactive Bladder
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Anticholinergics
5.2.2 Mirabegron
5.2.3 Botox
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Idiopathic Overactive Bladder
5.3.2 Neurogenic Overactive Bladder
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Anticholinergics
6.2.2 Mirabegron
6.2.3 Botox
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Idiopathic Overactive Bladder
6.3.2 Neurogenic Overactive Bladder
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Anticholinergics
7.2.2 Mirabegron
7.2.3 Botox
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Idiopathic Overactive Bladder
7.3.2 Neurogenic Overactive Bladder
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Anticholinergics
8.2.2 Mirabegron
8.2.3 Botox
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Idiopathic Overactive Bladder
8.3.2 Neurogenic Overactive Bladder
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Anticholinergics
9.2.2 Mirabegron
9.2.3 Botox
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Idiopathic Overactive Bladder
9.3.2 Neurogenic Overactive Bladder
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Astellas Pharma
10.1.2 Allergan
10.1.3 Pfizer
10.1.4 Teva (Activas)
10.1.5 Johnson & Johnson
10.2 Overactive Bladder Treatment Sales Date of Major Players (2017-2020e)
10.2.1 Astellas Pharma
10.2.2 Allergan
10.2.3 Pfizer
10.2.4 Teva (Activas)
10.2.5 Johnson & Johnson
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

Tables and Figures

List of Table
1.Table Overactive Bladder Treatment Product Type Overview
2.Table Overactive Bladder Treatment Product Type Market Share List
3.Table Overactive Bladder Treatment Product Type of Major Players
4.Table Brief Introduction of Astellas Pharma
5.Table Brief Introduction of Allergan
6.Table Brief Introduction of Pfizer
7.Table Brief Introduction of Teva (Activas)
8.Table Brief Introduction of Johnson & Johnson
9.Table Products & Services of Astellas Pharma
10.Table Products & Services of Allergan
11.Table Products & Services of Pfizer
12.Table Products & Services of Teva (Activas)
13.Table Products & Services of Johnson & Johnson
14.Table Market Distribution of Major Players
15.Table Global Major Players Sales Revenue (Million USD) 2017-2020e
16.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
17.Table Global Overactive Bladder Treatment Market Forecast (Million USD) by Region 2021f-2026f
18.Table Global Overactive Bladder Treatment Market Forecast (Million USD) Share by Region 2021f-2026f
19.Table Global Overactive Bladder Treatment Market Forecast (Million USD) by Demand 2021f-2026f
20.Table Global Overactive Bladder Treatment Market Forecast (Million USD) Share by Demand 2021f-2026f



List Of Figures
List of Figure
1.Figure Global Overactive Bladder Treatment Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
2.Figure Global Overactive Bladder Treatment Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
3.Figure Global Overactive Bladder Treatment Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
4.Figure Global Overactive Bladder Treatment Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
5.Figure Global Overactive Bladder Treatment Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
6.Figure Global Overactive Bladder Treatment Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
7.Figure Global Overactive Bladder Treatment Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
8.Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
9.Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
10.Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
11.Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
12.Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
13.Figure Anticholinergics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
14.Figure Mirabegron Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
15.Figure Botox Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
16.Figure Idiopathic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
17.Figure Neurogenic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
18.Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
19.Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
20.Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
21.Figure Anticholinergics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
22.Figure Mirabegron Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
23.Figure Botox Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
24.Figure Idiopathic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
25.Figure Neurogenic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
26.Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
27.Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
28.Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
29.Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
30.Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
31.Figure Anticholinergics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
32.Figure Mirabegron Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
33.Figure Botox Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
34.Figure Idiopathic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
35.Figure Neurogenic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
36.Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
37.Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
38.Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
39.Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
40.Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
41.Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
42.Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
43.Figure Anticholinergics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
44.Figure Mirabegron Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
45.Figure Botox Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
46.Figure Idiopathic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
47.Figure Neurogenic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
48.Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
49.Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
50.Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
51.Figure Anticholinergics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
52.Figure Mirabegron Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
53.Figure Botox Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
54.Figure Idiopathic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
55.Figure Neurogenic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
56.Figure GCC Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
57.Figure North Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
58.Figure South Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
59.Figure Rest of Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
60.Figure Anticholinergics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
61.Figure Mirabegron Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
62.Figure Botox Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
63.Figure Idiopathic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
64.Figure Neurogenic Overactive Bladder Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
65.Figure Overactive Bladder Treatment Sales Revenue (Million USD) of Astellas Pharma 2017-2020e
66.Figure Overactive Bladder Treatment Sales Revenue (Million USD) of Allergan 2017-2020e
67.Figure Overactive Bladder Treatment Sales Revenue (Million USD) of Pfizer 2017-2020e
68.Figure Overactive Bladder Treatment Sales Revenue (Million USD) of Teva (Activas) 2017-2020e
69.Figure Overactive Bladder Treatment Sales Revenue (Million USD) of Johnson & Johnson 2017-2020e
70.

Reason to Buy

  • Current and future of Medical Devices & Consumables Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Medical Devices & Consumables Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Medical Devices & Consumables Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Medical Devices & Consumables Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets